ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 68

Autophagy Activation Protects From Mitochondrial Dysfunction In Human Chondrocytes

Beatriz Caramés1, Paloma López de Figueroa2, Martin Lotz3 and Francisco J. Blanco4, 1Osteoarticular and Aging Research Lab, INIBIC–Complejo Hospitalario Universitario A Coruña, SPAIN, A Coruña, Spain, 2Cartilage Biology group. Rheumatology Division, INIBIC-A Coruña, Spain, A Coruña, Spain, 3The Scripps Research Institute, La Jolla, USA, La Jolla, CA, 4Osteoarticular and Aging Res. Lab. CIBER-BBN. INIBIC- University of A Coruña, A Coruña, Spain

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Aging, chondrocytes, mitochondria and osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Biology and Pathology of Bone and Joint (Cartilage and Osteoarthritis)

Session Type: Abstract Submissions (ACR)

Background/Purpose: A common feature of aging-related diseases, such as osteoarthritis (OA), is the progressive accumulation of damaged macromolecules leading to cell dysfunction and death. Autophagy, a key pathway for cellular homeostasis by removing such damaged molecules and organelles, including mitochondria, has a protective and survival-promoting function. Recent studies indicated that autophagy decreases with aging and OA contributing to the accumulation of damaged macromolecules. In addition, there is increasing evidence that mitochondrial dysfunction plays a critical role in accelerating the aging process and several lines of evidence demonstrated mitochondrial dysfunction in OA cartilage. The objective of this study is to determine whether activation of autophagy protects from mitochondrial dysfunction in human chondrocytes.

Methods: Human chondrocytes were treated with Rotenone (10 μg/ml), Antimycin (40 μg/ml) and Oligomycin (10 μg/ml), a mitochondrial respiratory chain (MRC) inhibitors of complex I, III and IV, respectively. Mitochondrial function and cell death were evaluated by Flow Cytometry (FC) and Fluorescence Microscopy (FM). Autophagy activation was analyzed by determination of LC3, a main marker of autophagy activation by Immunofluorescence (IF). To investigate whether autophagy protects from mitochondrial dysfunction, autophagy was induced by mTOR inhibition, using mTORC1 selective inhibitor Rapamycin (Rapa, 10 μM) and mTORC1 and mTORC2 inhibitor Torin 1 (50 nM). The effects on autophagy, mitochondrial function and chondrocyte viability were analyzed by IF, FC and FM.

Results:

Mitochondrial dysfunction was induced by 6 h treatment with MRC inhibitors, which significantly decreased mitochondrial membrane potential (Δψm) (ROT: 26.17 ± 5.9; AA: 18.21 ± 3.28; Oligo: 41.74 ± 7.59, expressed as % vs control; *p < 0.01). These results are consistent with increased ROS production (26.8 %, 44.6 % and 25.7 % for ROT, AA and Oligo, respectively; *p < 0.001) and cell death by apoptosis at 12 h (Control: 13.56 ± 1.83; ROT: 33.66 ± 5.55; AA: 29.05 ± 4.262; *p<0.05). Autophagy activity determined by LC3 expression significantly reduced in response to MRC inhibitors at 12 h. To evaluate whether autophagy regulates mitochondrial dysfunction, chondrocytes were pretreated with Rapa and Torin 1 for 4 h and then treated with the MRC inhibitors for 12 h. The results show an increase in LC3 expression compared to MRC inhibitors alone. Furthermore, autophagy inducers Rapa and Torin1 increased Δψm (Rapa: 125.8 ± 20.74; Rapa+ROT: 44.67 ± 10.37; Rapa+AA: 30.71 ± 5.949; Rapa ± Oligo: 108.5 ± 55.03 and Torin 1: 90.34 ± 9.17; Torin 1+ROT: 35.24 ± 2.7; Torin 1+AA: 41.98 ± 6.49; Torin 1+Oligo: 98.19 ± 16.81; *p<0.05), decreased ROS production (*p<0.05) and reduced cell death, suggesting a protective effect of autophagy activation on pharmacologically induced mitochondrial dysfunction.

Conclusion: These data identify autophagy activation as a protective mechanism from mitochondrial dysfunction in human chondrocytes. Pharmacological interventions that enhance autophagy may have chondroprotective activity in articular cartilage with defects on mitochondrial function.


Disclosure:

B. Caramés,
None;

P. López de Figueroa,
None;

M. Lotz,
None;

F. J. Blanco,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/autophagy-activation-protects-from-mitochondrial-dysfunction-in-human-chondrocytes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology